[Gastrointestinal stromal tumors. An update]

Pablo Bórquez Ma1, Rodrigo Neveu C

  • 1Instituto Nacional del Cancer. tellomora@yahoo.es

Revista Medica De Chile
|October 25, 2008
PubMed

Insights

Gastrointestinal stromal tumors (GIS) are CD 117-positive tumors with variable behavior. Molecular therapies like imatinib have improved survival, and this review covers prognostic factors and treatment options.

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Gastrointestinal stromal tumors (GIS) are a heterogeneous group of neoplasms expressing CD 117.
  • These tumors can range from benign to highly aggressive, impacting patient prognosis.
  • Recent advancements in molecular therapies have significantly improved survival rates for patients with GIS.

Purpose of the Study:

  • To analyze prognostic factors and clinical features of GIS.
  • To define criteria for identifying malignant behavior in GIS.
  • To discuss the efficacy of various therapeutic alternatives, including molecular therapies.

Main Methods:

  • Review of existing literature on GIS.
  • Analysis of prognostic indicators and clinical presentation.
  • Evaluation of therapeutic strategies: radiotherapy, chemotherapy, and molecular targeted therapies.

Main Results:

  • Identification of key prognostic factors influencing GIS behavior.
  • Established criteria for assessing the malignant potential of GIS.
  • Demonstrated improved patient survival with targeted molecular therapies.

Conclusions:

  • Understanding prognostic factors is crucial for managing GIS.
  • Molecular therapies represent a significant advancement in GIS treatment.
  • A comprehensive approach considering clinical features and therapeutic options is essential for optimal patient outcomes.